Invitae Corporation (NVTA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.51 |
| Open | 4.47 |
| Bid | 5.33 x 1400 |
| Ask | 5.40 x 3000 |
| Day's Range | 4.41 - 6.35 |
| 52 Week Range | 1.83 - 32.93 |
| Volume | |
| Avg. Volume | 17,615,759 |
| Market Cap | 1.263B |
| Beta (5Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.06 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NVTA
Related Research
- Invitae CorporationAnalyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.RatingFair ValueEconomic Moat3 days agoMorningstar
- Motley Fool
Is Soaring Invitae Stock a Smart Buy Now?
Shares of Invitae (NYSE: NVTA) recently shot up like a rocket in response to a second-quarter earnings call that was a lot more positive than expected. Bringing comprehensive genetic information into mainstream medicine could make Invitae a top performer in the years ahead. Let's look a little closer at the company's performance this year to see if it's a smart stock to buy now and hold for the long run.
- Motley Fool
Why Invitae Corporation Stock Jumped 23% This Week
Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 last Friday, then opened on Monday at $2.37. The stock has been volatile with a 52-week low of $1.83 and a high of $32.93.
- TipRanks
What’s behind the Invitae stock roller coaster? Morgan Stanley weighs in
Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock had nearly tripled in value before traders began cashing in some gains. In fact, on Thursday the stock has returned over half of yesterday’s gains, trading 47% lower. While investors were initially thrilled by the news, Morgan Stanley analyst Tejas Savant observed there were actually "no surprises" in
